US2016332962A1PendingUtilityA1

(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine

Assignee: JANSSEN PHARMACEUTICA NVPriority: May 13, 2015Filed: May 12, 2016Published: Nov 17, 2016
Est. expiryMay 13, 2035(~8.8 yrs left)· nominal 20-yr term from priority
A61P 9/12A61P 25/24A61P 25/04A61P 25/00A61P 11/00C07C 309/23C07C 2602/42C07B 2200/13C07C 309/19C07B 2200/07C07C 2601/14C07C 225/20C07C 303/32C07C 2101/14
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to processes for the preparation of esketamine. The present invention is further directed to processes for the resolution of S-ketamine from a racemic or enantiomerically enriched mixture of ketamine. The present invention is further directed to an (S)-CSA salt of S-ketamine, more particularly a monohydrate form of the (S)-CSA salt of S-ketamine, and to an (R)-CSA salt of R-ketamine.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . An (S)-camphorsulfonic acid salt of S-ketamine. 
     
     
         2 . An (S)-camphorsulfonic acid salt of S-ketamine as in  claim 1 , wherein the salt is a monohydrate. 
     
     
         3 . A crystalline monohydrate form of (S)-camphorsulfonic acid salt of S-ketamine. 
     
     
         4 . A crystalline monohydrate form as in  claim 3  comprising the following pXRD peaks: 
       
         
           
                 
                 
                 
               
                     
                 
                   position [°2θ] 
                   d-spacing [Å] 
                   relative intensity [%] 
                 
                     
                 
                     
                 
                 
                 
                 
               
                   7.76 
                   11.38 
                   58.03 
                 
                   8.11 
                   10.89 
                   21.58 
                 
                   12.75 
                   6.94 
                   24.89 
                 
                   13.13 
                   6.74 
                   55.99 
                 
                   13.31 
                   6.65 
                   23.96 
                 
                   13.64 
                   6.49 
                   31.52 
                 
                   14.92 
                   5.93 
                   100.00 
                 
                   15.51 
                   5.71 
                   32.12 
                 
                   15.71 
                   5.64 
                   28.46 
                 
                   18.45 
                   4.80 
                   43.84 
                 
                   24.22 
                   3.67 
                   25.66 
                 
                   25.26 
                   3.52 
                   28.46 
                 
                   27.33 
                   3.26 
                   51.32 
                 
                     
                 
             
                
                
                
               
               
                
               
            
             
                
                
                
                
                
                
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         5 . A crystalline monohydrate form as in  claim 3  comprising the following pXRD peaks: 
       
         
           
                 
                 
                 
               
                     
                 
                   position [°2θ] 
                   d-spacing [Å] 
                   relative intensity [%] 
                 
                     
                 
                     
                 
                 
                 
                 
               
                   7.76 
                   11.38 
                   58.03 
                 
                   8.11 
                   10.89 
                   21.58 
                 
                   12.75 
                   6.94 
                   24.89 
                 
                   13.13 
                   6.74 
                   55.99 
                 
                   13.31 
                   6.65 
                   23.96 
                 
                   13.64 
                   6.49 
                   31.52 
                 
                   14.92 
                   5.93 
                   100.00 
                 
                   15.51 
                   5.71 
                   32.12 
                 
                   15.71 
                   5.64 
                   28.46 
                 
                   18.45 
                   4.80 
                   43.84 
                 
                   21.29 
                   4.17 
                   12.49 
                 
                   22.38 
                   3.97 
                   14.87 
                 
                   23.26 
                   3.82 
                   10.45 
                 
                   24.22 
                   3.67 
                   25.66 
                 
                   25.26 
                   3.52 
                   28.46 
                 
                   26.76 
                   3.33 
                   13.93 
                 
                   27.33 
                   3.26 
                   51.32 
                 
                   28.21 
                   3.16 
                   12.32 
                 
                   29.13 
                   3.06 
                   11.05 
                 
                     
                 
             
                
                
                
               
               
                
               
            
             
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         6 . A process for the preparation of a monohydrate form of (S)-camphorsulfonic acid salt of S-ketamine comprising 
       
         
           
           
               
               
           
         
         reacting ketamine with (S)-camphorsulfonic acid, wherein the (S)-camphorsulfonic acid is present in an amount in the range of from about 0.5 to about 2.0 molar equivalents (relative to the molar amount of ketamine); 
         in the presence of water, wherein the water is present in an amount in the range of from about 3.5% to about 15%; 
         in an organic solvent; at a temperature in the range of from about 20° C. to about solvent reflux temperature; 
         to yield the corresponding monohydrate form of (S)-camphorsulfonic acid salt of S-ketamine; 
         wherein the monohydrate form of (S)-camphorsulfonic acid salt of S-ketamine is present in an enantiomeric excess in the range of from about 50% to about 100%. 
       
     
     
         7 . A process as in  claim 6 , wherein the (S)-camphorsulfonic acid is present in an amount in the range of from about 0.75 to about 1.2 molar equivalents. 
     
     
         8 . A process as in  claim 6 , wherein the (S)-camphorsulfonic acid is present in an amount in the range of from about 0.9 to about 1.1 molar equivalents. 
     
     
         9 . A process as in  claim 6 , wherein the water is present in an amount in the range of from about 5% to about 10%. 
     
     
         10 . A process as in  claim 6 , wherein the water is present in an amount in the range of from about 6% to about 8%. 
     
     
         11 . A process as in  claim 6 , wherein the organic solvent is selected from the group consisting of methyl ethyl ketone and 2-methyl-THF. 
     
     
         12 . A process as in  claim 6 , wherein the organic solvent is 2-methyl-THF. 
     
     
         13 . A process as in  claim 6 , wherein the ketamine is reacted with (S)-camphorsulfonic acid at a temperature in the range of from about 30° C. to about 100° C. 
     
     
         14 . A process as in  claim 6 , wherein the ketamine is reacted with (S)-camphorsulfonic acid at a temperature of about 50° C. to about 80° C. 
     
     
         15 . A process as in  claim 6 , wherein the monohydrate form of (S)-camphorsulfonic acid salt of S-ketamine is present in an enantiomeric excess in the range of from about 75% to about 100%. 
     
     
         16 . A process as in  claim 6 , wherein the monohydrate form of (S)-camphorsulfonic acid salt of S-ketamine is present in an enantiomeric excess in the range of from about 90% to about 100%. 
     
     
         17 . A process as in  claim 6 , wherein the monohydrate form of (S)-camphorsulfonic acid salt of S-ketamine is present in an enantiomeric excess of greater than or equal to about 96%. 
     
     
         18 . A process for the preparation of a monohydrate form of (S)-camphorsulfonic acid salt of S-ketamine comprising 
       
         
           
           
               
               
           
         
         reacting racemic ketamine with (S)-camphorsulfonic acid, wherein the (S)-camphorsulfonic acid is present in an amount of about 1 molar equivalents (relative to the molar amount of ketamine); 
         in the presence of water, wherein the water is present in an amount of in the range of from about 6% to about 8%; 
         in 2-methyl-THF; at a temperature of about 70° C., 
         to yield the corresponding monohydrate form of (S)-camphorsulfonic acid salt of S-ketamine; 
         wherein the monohydrate form of (S)-camphorsulfonic acid salt of S-ketamine is present in an enantiomeric excess in the range of from about 80% to about 100%. 
       
     
     
         19 . A product prepared according to the process of any of  claim 6 . 
     
     
         20 . A process according to  claim 6 , further comprising
 (a) reacting the monohydrate form of (S)-camphorsulfonic acid salt of S-ketamine with a base; in a solvent or mixture of solvents; to yield S-ketamine as a free base; and   (b) reacting the S-ketamine free base with HCl; to yield the corresponding S-ketamine hydrochloride salt.   
     
     
         21 . An (R)-camphorsulfonic acid salt of R-ketamine. 
     
     
         22 . An (R)-camphorsulfonic acid salt of R-ketamine as in  claim 21 , wherein the salt is crystalline. 
     
     
         23 . An (R)-camphorsulfonic acid salt of R-ketamine as in  claim 21 , wherein the salt is a hydrate. 
     
     
         24 . An (R)-camphorsulfonic acid salt of R-ketamine as in  claim 21 , wherein the salt is a monohydrate. 
     
     
         25 . A process for the preparation of (R)-camphorsulfonic acid salt of R-ketamine comprising 
       
         
           
           
               
               
           
         
         reacting ketamine with (R)-camphorsulfonic acid, wherein the (R)-camphorsulfonic acid is present in an amount in the range of from about 0.5 to about 2.0 molar equivalents (relative to the molar amount of ketamine); 
         in the presence of water, wherein the water is present in an amount in the range of from about 3.5% to about 15%; 
         in an organic solvent; at a temperature in the range of from about 20° C. to about solvent reflux temperature; 
         to yield a product mixture comprising (R)-camphorsulfonic acid salt of S-ketamine as a solid and S-ketamine; 
         wherein the (R)-camphorsulfonic acid salt of R-ketamine is present in an enantiomeric excess in the range of from about 50% to about 100%. 
       
     
     
         26 . A process as in  claim 25 , further comprising
 (a) filtering the product mixture to yield the (R)-camphorsulfonic acid salt of R-ketamine as a solid and a filtrate comprising S-ketamine;   (b) reacting the S-ketamine with HCl; to yield the corresponding S-ketamine hydrochloride salt.   
     
     
         27 . A process for the preparation of S-ketamine hydrochloride comprising the following steps:
 Step 1:   
       
         
           
           
               
               
           
         
         reacting ketamine with (R)-camphorsulfonic acid, wherein the (R)-camphorsulfonic acid is present in an amount in the range of from about 0.5 to about 2.0 molar equivalents (relative to the molar amount of ketamine); 
         in the presence of water, wherein the water is present in an amount in the range of from about 3.5% to about 15%; 
         in an organic solvent; at a temperature in the range of from about 20° C. to about solvent reflux temperature; 
         to yield a product mixture comprising (R)-camphorsulfonic acid salt of S-ketamine as a solid and S-ketamine in solution; wherein the (R)-camphorsulfonic acid salt of R-ketamine is present in an enantiomeric excess in the range of from about 50% to about 100%; 
         Step 2: 
       
       
         
           
           
               
               
           
         
         filtering the product mixture to yield the (R)-camphorsulfonic acid salt of R-ketamine as a solid and a filtrate comprising S-ketamine, and 
         Step 3: 
       
       
         
           
           
               
               
           
         
         reacting the S-ketamine with HCl; to yield the corresponding S-ketamine hydrochloride salt. 
       
     
     
         28 . A product prepared according to the process of  claim 25 . 
     
     
         29 . A product prepared according to the process of  claim 27 . 
     
     
         30 . A process for the preparation of S-ketamine or S-ketamine hydrochloride as described herein. 
     
     
         31 . A product prepared according to any of the processes described herein.

Join the waitlist — get patent alerts

Track US2016332962A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.